ECSP034762A - Nuevos compuestos antiinflamatorias de triazolopiridinas - Google Patents

Nuevos compuestos antiinflamatorias de triazolopiridinas

Info

Publication number
ECSP034762A
ECSP034762A EC2003004762A ECSP034762A ECSP034762A EC SP034762 A ECSP034762 A EC SP034762A EC 2003004762 A EC2003004762 A EC 2003004762A EC SP034762 A ECSP034762 A EC SP034762A EC SP034762 A ECSP034762 A EC SP034762A
Authority
EC
Ecuador
Prior art keywords
alkyl
nitrogen
hydrogen
triazolopiridines
group
Prior art date
Application number
EC2003004762A
Other languages
English (en)
Inventor
Mark Anthony Dombroski
Allen Jacob Duplantier
Kim Francis Mcclure
Michael A Letavic
Ellen R Laird
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP034762A publication Critical patent/ECSP034762A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a nuevas triazolopiridinas de fórmula I en al que Het es un heterociclo de 5 miembros opcionalmente sustituido que contiene uno a dos heteroátomos seleccionados de nitrógeno, azufre y oxígeno, debiendo ser nitrógeno al menos uno de dichos heteroátomos. R2 se selecciona del grupo constituido por hidrógeno, alquilo (C1-C6) u otros sustituyentes adecuados; R3 se selecciona del grupo constituido por hidrógeno alquilo (C1-C6) u otros sustituyentes adecuados: s es un número entero de cero a cinco; a intermediarios para su preparación, a composiciones farmacéuticas que los contienen y a su uso medicinal. Los compuestos de la presente invención son potentes inhibidores de las MAP quinasas, preferiblemente de la P38 quinasa. Son útiles en el tratamiento de la inflamación, osteroartritis, artritis reumatoide, cáncer, reperfusión o isquemia en la apoplejía o en el ataque cardíaco, enfermedades autoinmunes y otros trastornos.
EC2003004762A 2001-03-09 2003-09-09 Nuevos compuestos antiinflamatorias de triazolopiridinas ECSP034762A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27484001P 2001-03-09 2001-03-09

Publications (1)

Publication Number Publication Date
ECSP034762A true ECSP034762A (es) 2003-10-28

Family

ID=23049813

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004762A ECSP034762A (es) 2001-03-09 2003-09-09 Nuevos compuestos antiinflamatorias de triazolopiridinas

Country Status (37)

Country Link
US (1) US6696464B2 (es)
EP (1) EP1370559B1 (es)
JP (1) JP4130774B2 (es)
KR (1) KR20030080087A (es)
CN (1) CN1496366A (es)
AP (1) AP2002002463A0 (es)
AR (1) AR036152A1 (es)
AT (1) ATE323701T1 (es)
BG (1) BG108133A (es)
BR (1) BR0207990A (es)
CA (1) CA2440222C (es)
CR (1) CR7013A (es)
CZ (1) CZ20032185A3 (es)
DE (1) DE60210755T2 (es)
DO (1) DOP2002000353A (es)
EA (1) EA200300864A1 (es)
EC (1) ECSP034762A (es)
EE (1) EE200300437A (es)
ES (1) ES2260415T3 (es)
GT (1) GT200200042A (es)
HR (1) HRP20030719A2 (es)
HU (1) HUP0303415A2 (es)
IL (1) IL156567A0 (es)
IS (1) IS6858A (es)
MA (1) MA26991A1 (es)
MX (1) MXPA03008144A (es)
NO (1) NO20033969L (es)
NZ (1) NZ526528A (es)
OA (1) OA12552A (es)
PA (1) PA8541001A1 (es)
PE (1) PE20030010A1 (es)
PL (1) PL363959A1 (es)
SK (1) SK10272003A3 (es)
TN (1) TNSN02022A1 (es)
UY (1) UY27199A1 (es)
WO (1) WO2002072579A1 (es)
ZA (1) ZA200304983B (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372206B1 (en) * 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1854798A3 (en) * 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
GB0124934D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
US7087636B2 (en) * 2001-12-19 2006-08-08 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
CN100369898C (zh) * 2002-02-12 2008-02-20 史密丝克莱恩比彻姆公司 用作p38抑制剂的烟酰胺衍生物
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
US20040092547A1 (en) * 2002-08-30 2004-05-13 Pfizer Inc Alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US7005523B2 (en) 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
US7037923B2 (en) 2002-08-30 2006-05-02 Pfizer, Inc. Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US7012143B2 (en) 2002-08-30 2006-03-14 Dombroski Mark A Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
JP2006508914A (ja) * 2002-08-30 2006-03-16 ファイザー・プロダクツ・インク トリアゾロ−ピリジン製造のための新規な方法および中間体
US6949652B2 (en) 2002-08-30 2005-09-27 Pfizer, Inc. Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine
PA8579601A1 (es) 2002-08-30 2004-05-07 Pfizer Prod Inc Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
EP1601672B1 (en) 2003-02-14 2006-07-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
KR101099281B1 (ko) 2003-03-03 2011-12-26 어레이 바이오파마 인크. ｐ38 억제제 및 그의 사용 방법
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
GB0308185D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308201D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308186D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
AU2004305318A1 (en) * 2003-12-18 2005-07-07 Pfizer Products Inc. Methods of treating acute inflammation in animals with p38 MAP kinase inhibitors
GB0402143D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
TWI332003B (en) 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
JP2008504294A (ja) * 2004-06-25 2008-02-14 アムジエン・インコーポレーテツド サイトカイン介在疾患および他の疾患の治療において有用な縮合トリアゾールおよびインダゾール
KR100871535B1 (ko) 2004-08-12 2008-12-05 화이자 인코포레이티드 Ｐ38 ｍａｐ 키나아제 억제제로서의트리아졸로피리딘일설판일 유도체
AU2005273612B2 (en) * 2004-08-12 2010-10-14 Pfizer Inc. Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
JP2008509985A (ja) * 2004-08-18 2008-04-03 ファルマシア アンド アップジョン カンパニー リミテッド ライアビリティ カンパニー 炎症治療用の新規トリアゾロピリジン化合物
MX2007002050A (es) * 2004-08-18 2007-03-29 Pharmacia & Upjohn Co Llc Compuestos de triazolopiridina.
US20080051416A1 (en) * 2004-10-05 2008-02-28 Smithkline Beecham Corporation Novel Compounds
US7572807B2 (en) * 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7579360B2 (en) * 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
PE20070404A1 (es) * 2005-07-29 2007-05-10 Wyeth Corp Compuestos derivados de cianopirrol-sulfonamida como moduladores del receptor de progesterona
PE20070182A1 (es) 2005-07-29 2007-03-06 Wyeth Corp Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona
PE20070341A1 (es) * 2005-07-29 2007-04-13 Wyeth Corp Derivados de pirrol como moduladores del receptor de progesterona
WO2007089646A1 (en) 2006-01-31 2007-08-09 Array Biopharma Inc. Kinase inhibitors and methods of use thereof
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
ES2301380B1 (es) 2006-08-09 2009-06-08 Laboratorios Almirall S.A. Nuevos derivados de 1,7-naftiridina.
CN101553224A (zh) 2006-10-06 2009-10-07 艾博特公司 新型咪唑并噻唑和咪唑并唑
GEP20125658B (en) 2006-11-22 2012-10-10 Incyte Corp Imidazotriazines and imidazo pyrimidines as kinase inhibitors
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
ES2329639B1 (es) 2007-04-26 2010-09-23 Laboratorios Almirall S.A. Nuevos derivados de 4,8-difenilpoliazanaftaleno.
WO2009005675A1 (en) * 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
CA2691448A1 (en) 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
SI2300455T1 (sl) 2008-05-21 2017-12-29 Incyte Holdings Corporation Soli 2-fluoro-n-metil-4-(7-(kinolin-6-il-metil)-imidazo(1,2-b)1,2,4) triazin-2-il)benzamid in postopki v zvezi z njihovo pripravo
US8987251B2 (en) 2008-08-19 2015-03-24 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
WO2010022081A1 (en) 2008-08-19 2010-02-25 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物
US8895550B2 (en) 2008-08-19 2014-11-25 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
HUE034911T2 (hu) 2009-07-27 2018-03-28 Gilead Sciences Inc Fúzionált heterociklusos vegyületek mint ioncsatorna modulátorok
EP2322176A1 (en) 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
MX2012008898A (es) 2010-02-03 2012-11-06 Incyte Corp Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met.
EP2588197B1 (en) 2010-07-02 2014-11-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
WO2012065297A1 (en) * 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
MX339899B (es) 2011-02-25 2016-06-16 Array Biopharma Inc Compuestos de triazolopiridina como inhibidores de pim cinasa.
WO2012154760A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
NO3175985T3 (es) 2011-07-01 2018-04-28
CN105263490B (zh) * 2013-03-14 2018-05-22 基因泰克公司 取代的三唑并吡啶及其使用方法
GB201321742D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2015157955A1 (en) * 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
ES2927715T3 (es) 2017-10-05 2022-11-10 Fulcrum Therapeutics Inc Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD
CN116514801B (zh) * 2022-01-20 2024-11-08 四川大学 2-苯基-[1,2,4]三唑并[1,5-a]吡啶类化合物、其氮氧化物及用途
CN114504636B (zh) * 2022-01-27 2023-09-26 华南理工大学 一种杏仁油烫伤膏及其制备方法与应用
CN119997982A (zh) 2022-09-09 2025-05-13 迈里克斯制药有限公司 包含nmt抑制剂的抗体药物偶联物及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US576499A (en) * 1897-02-02 Gas apparatus
US5716972A (en) * 1993-01-13 1998-02-10 Smithkline Beecham Corporation Pyridyl substituted imidazoles
US5871934A (en) 1993-09-17 1999-02-16 Smithkline Beecham Corporation Screening methods using cytokine suppressive anti-inflammatory drug (CSAID) binding proteins
IT1269176B (it) * 1994-01-11 1997-03-21 Isagro Srl Eterobicicli ad attivita' fungicida
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US5756499A (en) 1996-01-11 1998-05-26 Smithkline Beecham Corporation Substituted imidazole compounds
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
CA2333157A1 (en) 1998-05-26 1999-12-02 Smithkline Beecham Corporation Novel substituted imidazole compounds
US6207687B1 (en) * 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
US6350744B1 (en) 1998-11-20 2002-02-26 Merck & Co., Inc. Compounds having cytokine inhibitory activity
EP1140916B1 (en) 1998-12-16 2002-11-13 Aventis Pharma Limited Heteroaryl-cyclic acetals
EP1140083A4 (en) 1999-01-08 2004-01-02 Smithkline Beecham Corp NEW CONNECTIONS
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
CO5170501A1 (es) 1999-04-14 2002-06-27 Novartis Ag AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO

Also Published As

Publication number Publication date
KR20030080087A (ko) 2003-10-10
GT200200042A (es) 2003-02-11
UY27199A1 (es) 2002-10-31
BG108133A (bg) 2004-09-30
CA2440222A1 (en) 2002-09-19
CZ20032185A3 (en) 2004-06-16
EP1370559B1 (en) 2006-04-19
US6696464B2 (en) 2004-02-24
IS6858A (is) 2003-06-23
HRP20030719A2 (en) 2005-04-30
ATE323701T1 (de) 2006-05-15
MXPA03008144A (es) 2003-12-12
TNSN02022A1 (fr) 2005-12-23
HUP0303415A2 (hu) 2004-01-28
WO2002072579A1 (en) 2002-09-19
CA2440222C (en) 2008-11-18
NO20033969L (no) 2003-10-13
EP1370559A1 (en) 2003-12-17
EA200300864A1 (ru) 2003-12-25
PE20030010A1 (es) 2003-01-29
US20030096838A1 (en) 2003-05-22
ES2260415T3 (es) 2006-11-01
AR036152A1 (es) 2004-08-18
SK10272003A3 (sk) 2004-07-07
CN1496366A (zh) 2004-05-12
IL156567A0 (en) 2004-01-04
EE200300437A (et) 2004-02-16
PL363959A1 (en) 2004-11-29
MA26991A1 (fr) 2004-12-20
NZ526528A (en) 2005-02-25
ZA200304983B (en) 2004-06-29
OA12552A (en) 2006-06-06
NO20033969D0 (no) 2003-09-08
BR0207990A (pt) 2004-04-27
PA8541001A1 (es) 2003-05-14
CR7013A (es) 2003-11-25
JP4130774B2 (ja) 2008-08-06
JP2004522799A (ja) 2004-07-29
AP2002002463A0 (en) 2002-06-30
DE60210755T2 (de) 2006-11-16
DE60210755D1 (de) 2006-05-24
DOP2002000353A (es) 2002-10-15

Similar Documents

Publication Publication Date Title
DOP2002000353A (es) Nuevos compuestos antiinflamatorios de triazolopiridinas
DOP2002000349A (es) Nuevos compuestos antiinflamatorios de bencimidazol
CA2379903A1 (en) Novel benzotriazoles anti-inflammatory compounds
MXPA05008568A (es) Nuevos compuestos anti-inflamatorios triazolo-piridinas.
ES2204539T3 (es) Derivados de piridina y pirimidina y su uso como inhibidores de enfermedades mediadas por citoquinas.
GT200000002A (es) Ureas difenilicias x - carboxyaril sustituidas como inhibidores raf kinase.
AP2000001964A0 (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation.
BG106527A (en) Pharmaceutically active sulfonamide derivatives
RU94031155A (ru) Амидин - производные, способ их получения, их использование в качестве ингибиторов no - синтазы, фармсостав, способ лечения
AR048642A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento
AR029383A1 (es) Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes
ES2134926T3 (es) Derivados vinileno-azaindolicos y su procedimiento de preparacion.
AR023659A1 (es) Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos
NO20024154L (no) Pyrimidinforbindelser
FI884879A0 (fi) Terapeutiskt anvaendbara heterocykliska foereningar.
MA23433A1 (fr) Nouvelles compositions leurs procedes de preparation et leur emploi
CO5261551A1 (es) Nuevos derivados de biarileter utiles como inhibidores de la recaptacion de monoaminas
YU64092A (sh) Fluoralkoksibenzamino derivati heterocikličnih jedinjenja koja sadrže azot
MX9300031A (es) Derivados de piperazina, procedimiento para su preparacion y composicion farmaucetica que los contiene.
ATE425142T1 (de) Inhibitoren von c-jun n-terminal kinasen (jnk)
TW200420562A (en) Di and trifluoro-triazolo-pyridines anti-inflammatory compounds
SE8307133D0 (sv) Carboxamido-derivatives of 5h-1,3,4-thiadiazolo(3,2-a)pyrimidines and process for their preparation
ES2920888T3 (es) Derivado de sulfonamida y método de preparación y uso del mismo
BR0313961A (pt) Processos e intermediários para preparar triazolo-piridinas
BRPI0417928A (pt) composto, composição farmacêutica, métodos para o tratamento ou a prevenção de uma condição mediada pelo receptor de bradicinina b1, e de dor em um mamìfero, e, uso de um composto